北京纽维珀奥医药科技

NewVipero is a Beijing-based biotechnology company specializing in the discovery and development of innovative peptide therapeutics derived from natural venoms. The company utilizes its proprietary Vipero-Discovery platform, which integrates toxinomics, bioinformatics, and peptide engineering to identify bioactive molecules with high therapeutic potential. Their research primarily targets metabolic diseases, chronic pain, and cardiovascular conditions by leveraging the unique selectivity of animal toxins. The lead candidate, NV-001, is a multi-agonist peptide targeting GLP-1, GIP, and glucagon receptors for the treatment of obesity and type 2 diabetes. NewVipero aims to transform complex natural toxins into safe and effective medicines for global markets. The company is supported by prominent Chinese venture capital firms and maintains a strong focus on early-stage R&D.